> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Meissa Gains Fast Track for RSV Infection Vaccine
- URL: https://www.fdaweb.com/meissa-gains-fast-track-for-rsv-infection-vaccine/
- Published: 2020-01-10T12:00:00.000Z
- Updated: 2026-09-14T15:58:16.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5145818

FDA has granted Meissa Vaccines a fast track designation for MV-012-968, an investigational, live attenuated vaccine for protection against respiratory syncytial virus (RSV) infection. RSV is the most common cause of acute lower respiratory tract infections in young children and infects nearly all children by two years of age, the company says. Meissa says it will use th designation to request early and frequent interactions with FDA reviewers to discuss all aspects of the clinical development plan for MV-012-968 to ensure that the appropriate data are collected to support a vaccine licensure application. A Phase 1 clinical trial evaluating MV-012-968 is presently recruiting healthy adult volunteers.